.

.

.

.

The Australian Pancreatic Cancer Genome Initiative (APGI), the NSWCC and NHMRC funded research program that has helped set the standards for characterizing the genomic underpinnings of pancreatic cancer on a large scale, is moving to its next phase under new leadership.

The APGI has prospered under the leadership of Andrew Biankin, whom after his 2013 relocation to Glasgow, is stepping down as Chairman.  Anthony Gill, a specialist pancreatic pathologist and member of the APGI Executive since its inception in 2009, will take up the reigns in his appointment as the new Chairman at the end of the year.  Anthony brings renewed direction and unique experience to the APGI and we welcome him warmly into the role.  We thank Andrew for his leadership and look forward to his continuing involvement as a member of the executive committee.

New leadership and enhanced focus bring the opportunity to re-structure and expand the APGI to allow us to move forward into the future.  Development of several new projects is already underway so stay tuned for more information on the next phase.